Details of the Drug Combination

General Information of Drug Combination (ID: DCU0X00)

Drug Combination Name
TEM ER819762
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs TEM   DMLNFWU ER819762   DMSG91J
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: HCC-2998
Zero Interaction Potency (ZIP) Score: 1.66
Bliss Independence Score: 5.08
Loewe Additivity Score: 5.26
LHighest Single Agent (HSA) Score: 3.09

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of TEM
Disease Entry ICD 11 Status REF
Postherpetic neuralgia 1E91.5 Phase 2 [2]
Indication(s) of ER819762
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
ER819762 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Antagonist [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCY88JM HL-60(TB) Investigative [5]
Anaplastic large cell lymphoma DC7WWH5 SR Investigative [5]
Glioma DCMCID3 SF-295 Investigative [5]
Papillary renal cell carcinoma DCO2IZ5 ACHN Investigative [5]
Carcinoma DCZ695P RXF 393 Investigative [6]
Adenocarcinoma DC6QEMY OVCAR3 Investigative [1]
Lung adenocarcinoma DCU9SGC EKVX Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4040).
4 A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.